Last mentioned: 1h ago
Analyst Target Cuts
TD Cowen and Canaccord Genuity slash price targets citing competitive risks and valuation.
Market Volatility
VEEV stock surges 11% on long-term outlook before retreating on disclosure concerns.
Q4 Earnings Report
Veeva reports advancing income and sets a $6B revenue target for 2030.
Competitive Disclosure
Management reveals competitive losses in the CRM segment during the earnings call.
TD Cowen Conference
AbbVie management is scheduled to speak at the TD Cowen Health Care Conference.
DOJ Legal Support
The Department of Justice backs AbbVie in its challenge against a Colorado drug discount program law.
RBC Coverage Launch
RBC Capital Markets initiates coverage with an Outperform rating, citing durable growth.
Humira Exclusivity Ends
The first biosimilar for Humira enters the U.S. market, marking the start of the 'Humira cliff'.
Veeva Systems (VEEV) is navigating a complex post-earnings landscape as major analysts, including TD Cowen and Canaccord Genuity, significantly lower their price targets. Despite a bullish long-term revenue outlook, recent management disclosures regarding competitive losses have triggered a wave of valuation adjustments across Wall Street.
RBC Capital has initiated coverage of AbbVie with an 'Outperform' rating, signaling confidence in the company's ability to navigate the post-Humira landscape. Analysts believe the market has over-discounted the growth potential of AbbVie's next-generation immunology drugs and its durable aesthetics portfolio.
TD Cowen has downgraded digital intelligence leader Cellebrite (CLBT), citing a broader contraction in the forensics market. Despite the company's robust annual recurring revenue growth, analysts warn that tightening government budgets and market saturation could limit near-term upside.